Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease

Journal of Neuroscience Research

Volumn 93, Issue 9, 2015, Pages 1325-1329

  Li, Yuanli ^a   Wang, Junqing ^a   Zhang, Shenghao ^a   Liu, Zhaohui ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid ; Gene therapy; Gene transfer; Neprilysin

Indexed keywords

AMYLOID BETA PROTEIN; MEMBRANE METALLOENDOPEPTIDASE;

ALZHEIMER DISEASE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; REVIEW; VIRAL GENE THERAPY; ANIMAL; GENE THERAPY; GENETICS; PHYSIOLOGY; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; GENETIC THERAPY; HUMANS; NEPRILYSIN;

EID: 84948121451     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23564     Document Type: Review

References (36)

1. Adlard PA, James SA, Bush AI, Masters CL. 2009. beta-Amyloid as a molecular therapeutic target in Alzheimer's disease. Drugs Today 45:293-304.
2. Boulaiz H, Marchal JA, Prados J, Melguizo C, Aranega A. 2005. Nonviral and viral vectors for gene therapy. Cell Mol Biol 51:3-22.
3. Burns A, Iliffe S. 2009. Alzheimer's disease. Br Med J 338:b158.
4. Dean DA. 2005. Nonviral gene transfer to skeletal, smooth, and cardiac muscle in living animals. Am J Physiol Cell Physiol 289:C233-C245.
5. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. 2008. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 172:1342-1354.
6. Goldsworthy MR, Vallence AM. 2013. The role of beta-amyloid in Alzheimer's disease-related neurodegeneration. J Neurosci 33:12910-12911.
7. Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. 2013. Neprilysin and Abeta clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer's disease. Front Aging Neurosci 5:98.
8. Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP, Hersh LB. 2009. Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res 87:1462-1473.
9. Gunther EC, Strittmatter SM. 2010. beta-Amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med 88:331-338.
10. Hong CS, Goins WF, Goss JR, Burton EA, Glorioso JC. 2006. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 13:1068-1079.
11. Ibraheem D, Elaissari A, Fessi H. 2014. Gene therapy and DNA delivery systems. Int J Pharm 459:70-83.
12. Ijiri D, Saegusa A, Matsubara T, Kanai Y, Hirabayashi M. 2012. In vivo gene transfer into skeletal muscle of neonatal chicks by electroporation. Anim Sci J 83:504-509.
13. Iwata N, Mizukami H, Shirotani K, Takaki Y, Muramatsu S, Lu B, Gerard NP, Gerard C, Ozawa K, Saido TC. 2004. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-beta peptide in mouse brain. J Neurosci 24:991-998.
14. Kanemitsu H, Tomiyama T, Mori H. 2003. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 350:113-116.
15. Li Y, Wang J, Liu J, Liu F. 2010. A novel system for in vivo neprilysin gene delivery using a syringe electrode. J Neurosci Methods 193:226-231.
16. Li Y, Wang J, Grebogi C, Foote M, Liu F. 2012a. A syringe-focused ultrasound device for simultaneous injection of DNA and gene transfer. J Gene Med 14:54-61.
17. Li Y, Wang J, Satterle A, Wu Q, Liu F. 2012b. Gene transfer to skeletal muscle by site-specific delivery of electroporation and ultrasound. Biochem Biophys Res Commun 424:203-207.
18. Liu F, Liang KW, Huang L. 2001. Systemic administration of naked DNA: gene transfer to skeletal muscle. Mol Interv 1:168-172.
19. Liu Y, Studzinski C, Beckett T, Guan H, Hersh MA, Murphy MP, Klein R, Hersh LB. 2009. Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther 17:1381-1386.
20. Liu Y, Studzinski C, Beckett T, Murphy MP, Klein RL, Hersh LB. 2010. Circulating neprilysin clears brain amyloid. Mol Cell Neurosci 45:101-107.
21. Lundstrom K, Boulikas T. 2003. Viral and nonviral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2:471-486.
22. Marr RA, Rockenstein E, Mukherjee A, Kindy MS, Hersh LB, Gage FH, Verma IM, Masliah E. 2003. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 23:1992-1996.
23. Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K. 2003. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23:29-33.
24. Mir LM, Bureau MF, Rangara R, Schwartz B, Scherman D. 1998. Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. CR Acad Sci III 321:893-899.
25. Murakami T, Sunada Y. 2011. Plasmid DNA gene therapy by electroporation: principles and recent advances. Curr Gene Ther 11:447-456.
26. Nayerossadat N, Maedeh T, Ali PA. 2012. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 1:27.
27. Pacak CA, Walter GA, Gaidosh G, Bryant N, Lewis MA, Germain S, Mah CS, Campbell KP, Byrne BJ. 2007. Long-term skeletal muscle protection after gene transfer in a mouse model of LGMD-2D. Mol Ther 15:1775-1781.
28. Pennant WA, An S, Gwak SJ, Choi S, Banh DT, Nguyen AB, Song HY, Ha Y, Park JS. 2014. Local nonviral gene delivery of apoptin delays the onset of paresis in an experimental model of intramedullary spinal cord tumor. Spinal Cord 52:3-8.
29. Perez-Gracia E, Blanco R, Carmona M, Carro E, Ferrer I. 2009. Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimer's disease. Acta Neuropathol 118:497-504.
30. Poirier R, Wolfer DP, Welzl H, Tracy J, Galsworthy MJ, Nitsch RM, Mohajeri MH. 2006. Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. Neurobiol Dis 24:475-483.
31. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80:148-158.
32. Tzen KY, Yang SY, Chen TF, Cheng TW, Horng HE, Wen HP, Huang YY, Shiue CY, Chiu MJ. 2014. Plasma Aβ but not tau related to brain PiB retention in early Alzheimer's disease. ACS Chem Neurosci 5:830-836.
33. Verdile G, Fuller S, Atwood CS, Laws SM, Gandy SE, Martins RN. 2004. The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 50:397-409.
34. Wisniewski T, Ghiso J, Frangione B. 1997. Biology of A beta amyloid in Alzheimer's disease. Neurobiol Dis 4:313-328.
35. Wood LS, Pickering EH, McHale D, Dechairo BM. 2007. Association between neprilysin polymorphisms and sporadic Alzheimer's disease. Neurosci Lett 427:103-106.
36. Zolochevska O, Xia X, Williams BJ, Ramsay A, Li S, Figueiredo ML. 2011. Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum Gene Ther 22:1537-1550.